Completed PHASE3 INTERVENTIONAL 2-arm NCT00054587

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects

Sponsor: UNICANCER

Conditions Breast Cancer

Interventions Cyclophosphamide Epirubicin Fluorouracil Trastuzumab docetaxel

Updated 6 times since 2017 Last updated: Jul 18, 2013 Started: Jun 30, 2001 Primary completion: Jun 30, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00054587, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by UNICANCER, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UNICANCER

Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Annecy, France , Bordeaux, France , Bourg-en-Bresse, France , Caen, France , Clermont-Ferrand, France , Créteil, France , Dijon, France , Grenoble, France , Harfleur, France and 18 more locations